Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers Health shows impressive operating leverage and a scalable business model, with massive growth potential from new ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy ...

Hims & Hers rebounds with key partnerships and launches, achieving 111% YoY revenue growth. Learn more about HIMS stock here.

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Pharmaceutical company Novo Nordisk is teaming up with direct-to-consumer telehealth company Hims & Hers to offer discounted access to Wegovy, a GLP-1 manufactured by Novo Nordisk, the companies ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...